Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers

• DOI: 10.2147/ijn.s299443
• Publication Date: 2021-05-10T21:25:32Z
• Authors: Guo Yu; Zakir Ali; Anam Sajjad Khan; Kalim Ullah; Humzah Jamshaid; Alam Zeb; Muhammad Imran; Sadia Sarwar; Han-Gon Choi; Fakhar ud Din
• Keywords: Miltefosine; Biodistribution

Background: The purpose of this study was to investigate the suitability nanostructured lipid carriers (NLCs) loaded with miltefosine (HePC) as an anticancer drug for treatment breast cancer. Methods: HePC-NLCs were prepared using a microemulsion technique and then evaluated particle size, polydispersity index (PDI), incorporation efficiency, in vitro release entrapped drug, hemolytic potential. Furthermore, pharmacokinetic, biodistribution, liver toxicity analyses performed Sprague–Dawley rats, antitumor efficacy Michigan Cancer Foundation-7 (MCF-7) squamous cell carcinoma-7 (SCC-7) cells tumour-bearing BALB/c mice vivo. Advanced including survival rate, immunohistopathology, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays evaluate apoptosis Results: average size 143 ± 16 nm, narrow PDI (0.104 0.002), efficiency found be 91 7%. NLCs released HePC sustained manner, significantly lower than that free drug. assay demonstrated reduced potential (∼ 9%) compared test formulations. enhanced pharmacokinetic behaviour over extended blood circulation abridged clearance rate rats. exhibited higher cytotoxicity MCF-7 SCC-7 cells. Moreover, showed ( P < 0.005) activity control drug-treated mouse groups. Tumour also confirmed, indicating HePC-NLCs. Conclusion: These findings demonstrate ability delivery system antitumor, apoptotic effects, most importantly when HePC. Keywords: cancer, miltefosine, nano carriers, bioavailability, pharmacokinetics,